Procept Biorobotics Corp (PRCT) financials
Procept Biorobotics revenue and earnings by year
Procept Biorobotics's revenue was $308 million in the fiscal year to December 31, 2025, up 37.2% from the year before. Net income was -$95.6 million, -31.0% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 91.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 308 | 224 | 136 | 75 | 34 | 8 | 6 |
| Revenue growth | 37.2% | 64.8% | 81.6% | 117.6% | 346.7% | 25.1% | — |
| Gross profit | 196 | 137 | 71 | 37 | 16 | -1 | -2 |
| Gross margin | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% | -16.3% | -30.6% |
| Operating income | -104 | -97 | -109 | -81 | -54 | -48 | -44 |
| Operating margin | -33.7% | -43.0% | -80.2% | -107.6% | -157.1% | -619.4% | -705.9% |
| Net income | -96 | -91 | -106 | -87 | -60 | -53 | -42 |
| Net margin | -31.0% | -40.7% | -77.8% | -116.2% | -173.6% | -687.0% | -680.4% |
| Diluted EPS | -$1.72 | -$1.75 | -$2.24 | -$1.96 | -$3.63 | — | — |
| Free cash flow | -58 | -104 | -133 | -83 | -58 | -49 | -51 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PRCT in Markets.
See also: PRCT returns
No forecast, no recommendation. This page describes Procept Biorobotics Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.